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Ceftriaxone acted synergistically with levofloxacin in time–killing assays in vitro over 8 h against two penicillin-
resistant pneumococcal strains (WB4 and KR4; MIC of penicillin: 4 mg/L). Synergy was confirmed with the
chequerboard method, showing FIC indices of 0.25. In the experimental rabbit meningitis model, ceftriaxone
(1× 125 mg/kg) was slightly less bactericidal (–0.30 ∆log10 cfu/mL.h) compared with levofloxacin (–0.45 ∆log10
cfu/mL.h) against the penicillin-resistant strain WB4. The combination therapy (levofloxacin and ceftriaxone)
was significantly superior (–0.64 ∆log10 cfu/mL.h) to either monotherapy. In cycling experiments in vitro, the
addition of ceftriaxone at a sub-MIC concentration (1/16 MIC) reduced levofloxacin-induced resistance in the
two strains KR4 and WB4. After 12 cycles with levofloxacin monotherapy, the MIC increased 64-fold in both
strains versus a 16-fold increase with the combination (levofloxacin + ceftriaxone 1/16 MIC). In both strains,
levofloxacin-induced resistance was confirmed by mutations detected in the genes parC and gyrA, encod-
ing for subunits of topoisomerase IV and gyrase, respectively. The addition of ceftriaxone suppressed
mutations in parC but led to a new mutation in parE in both strains.
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Introduction
The worldwide increase in penicillin-resistant strains has complicated
the treatment of pneumococcal infections. In the USA, resistance
rates have reached 51%, with 33% of the strains showing intermediate
resistance in recent years.1 A recently published survey from Switzer-
land also revealed an increasing tendency towards resistance, with
overall rates of 13%.2 Additional resistance to cephalosporins in
some cases has further jeopardized the usefulness of β-lactam anti-
biotics in pneumococcal diseases. In addition, quinolone-resistant
strains have been isolated.3 The report of quinolone treatment failure
due to the emergence of quinolone resistance during treatment has
thrown the role of quinolone monotherapy in pneumococcal diseases
into question.4 Until now, β-lactam antibiotics have remained the
drugs of choice for pneumococcal diseases, except when their pene-
tration into infected tissues is limited, as is the case in meningitis.
Published guidelines advise a combination of a cephalosporin with
vancomycin for the empirical treatment of meningitis, especially
when cephalosporin-resistant strains are suspected.5 On the other
hand, the recent isolation of cephalosporin- and vancomycin-tolerant
strains might lead to eradication failures and reduce the utility of this
antibiotic combination.6 A highly bactericidal antibiotic combin-
ation with excellent tissue penetration that does not lead to the emer-
gence of resistance would be a major advantage in the treatment of
pneumococcal diseases. For more than a decade, ceftriaxone has
been the established monotherapy for these infections. The aim of
this study was to investigate the potential synergy between ceftriaxone
and levofloxacin, both with good activity against pneumococci, in
vitro and in experimental meningitis and to test the effect of ceftriaxone
on levofloxacin-induced resistance in vitro.
Methods
Strains and MIC determination
The two pneumococcal strains (WB4 and KR4) were originally isolated
from two patients with pneumonia at the University Hospital of Bern,
Switzerland. The MICs for WB4 were: penicillin 4 mg/L, ceftriaxone
0.5 mg/L, cefotaxime 1 mg/L, vancomycin 0.12–0.25 mg/L, levofloxacin
1 mg/L, gatifloxacin 0.12–0.25 mg/L, moxifloxacin 0.12 mg/L and
garenoxacin 0.03 mg/L. The MICs for KR4 were: penicillin 4 mg/L,
ceftriaxone 0.5 mg/L, cefotaxime 1 mg/L, vancomycin 0.12–0.25 mg/L,
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levofloxacin 1 mg/L, gatifloxacin 0.25 mg/L, moxifloxacin 0.12 mg/L
and garenoxacin 0.015 mg/L.
MICs were determined by broth macrodilution. The MIC was defined
as the lowest concentration that inhibited visible growth after 12 and 24 h
of incubation at 37°C.
Rabbit meningitis model
The meningitis model described by Dacey & Sande7 was used in this
study. The experimental protocol was accepted by the local ethics
committee (Veterinäramt des Kantons Bern). Young New Zealand white
rabbits weighing 2–2.5 kg were anaesthetized by intramuscular injection
of ketamine (30 mg/kg) and xylazine (15 mg/kg) and were immobilized
in stereotactic frames for induction of meningitis and cfu sampling. An
inoculum containing ∼105 cfu of the penicillin-resistant strain WB4 was
instilled in the cisterna magna. A long-acting anaesthetic drug [ethyl-
carbamate (urethane): 3.5 g/rabbit] was injected subcutaneously, and
animals were returned to their cages. Fourteen hours later the cisterna
magna was punctured again for periodic CSF sampling before and 1, 2, 4,
5, 6 and 8 h after initiation of therapy. Anaesthesia was performed by
repeat injections of pentobarbital sodium (Nembutal). Antibiotics were
administered via a peripheral ear vein at the following concentrations:
ceftriaxone 125 mg/kg and levofloxacin 10 mg/kg of body weight.
Ceftriaxone and levofloxacin were injected once at hour zero. All anti-
biotics and anaesthetic drugs were purchased commercially.
Bacterial titres were measured by 10-fold serial dilutions of CSF
samples, then plated on blood agar plates containing 5% sheep blood,
and incubated overnight at 37°C. In parallel, 20 µL aliquots of undiluted
samples were plated (limit of detectability: 50 cfu/mL). Comparisons
between dilutions of CSF were used to exclude significant carryover
effects during therapy. The antimicrobial activity of the different regi-
mens during the 8 h treatment was calculated by linear regression analy-
sis and expressed as a change in log10 cfu/mL.h and as a change in viable
count over 8 h. A value of 1.7 (log10 of the limit of detectability) was
assigned to the first sterile CSF sample, and a value of zero was assigned
to any subsequent sterile CSF sample. The results are expressed as means
± S.D. Statistical significance was determined by the Newman–Keuls test.
Determination of antibiotic levels in CSF
Antibiotic concentrations in the CSF were measured by agar diffusion.
Standard curves were performed in saline with 5% rabbit serum in order
to mimic CSF protein concentrations.8 Bacillus subtilis ATCC 6633 was
used as a test strain for levofloxacin9 and Escherichia coli (ATCC 25922)
for ceftriaxone.10 The inter- and intraday variability was in the range
5%–10%. The limits of detection were 0.5 mg/L for ceftriaxone and
0.3 mg/L for levofloxacin.
In vitro killing assays
The two pneumococcal strains (WB4 and KR4) were grown in C+Y11 to
an optical density of 0.3 at 590 nm and then diluted 40-fold to 106 cfu,
corresponding approximately to the CSF bacterial titre in rabbits before
initiation of therapy. Ceftriaxone was added at a sub-MIC concentration
(1/2 MIC against KR4 and WB4) and levofloxacin at the concentration
corresponding to the MIC. Bacterial titres were determined at 0, 2, 4, 6
and 8 h by serial dilution of samples, plated on agar plates containing 5%
sheep blood and incubated at 37°C for 24 h. Experiments were performed
in triplicate and results are expressed as means ± S.D.
Determination of fractional inhibitory concentration (FIC) 
index
FIC indices were measured using the chequerboard method, as described
previously.12 In brief, the two pneumococcal strains (WB4 and KR4)
were grown in C+Y medium until the logarithmic growth phase (optical
density of 0.3 at 590 nm) and were then diluted 1:40. Approximately
0.5–1 × 106 cfu were pipetted into microtitre trays containing concen-
trations of levofloxacin and ceftriaxone that ranged from 1/32 × MIC to
2 × MIC. Microtitre plates were incubated at 37°C for 24 h. After 6, 12
and 24 h the plates were read for detection of inhibition of bacterial
growth. The experiments were performed in duplicate and repeated once.
FIC indices were calculated by the method of Eliopoulos & Moellering.13
Synergy was defined as an FIC index of ≤0.5, indifference as an FIC
index of >0.5 to ≤4 and antagonism as an FIC index of >4.
Selection of quinolone-resistant derivatives in vitro
Experiments were designed to test the tendency of levofloxacin to select
resistant strains in liquid cultures. Large inocula (107–108 cfu/mL) of
either WB4 or KR4 were exposed to stepwise increasing concentrations
of antibiotics.14 Series of tubes containing two-fold increasing con-
centrations of levofloxacin were incubated either with WB4 or KR4
(107–108 cfu/mL), as for MIC determination. After 12 h of incubation,
0.1 mL samples from the tubes containing the highest antibiotic concen-
tration and still showing turbidity were used to inoculate a new series
of tubes containing antibiotic serial dilutions. The experiments were
performed over 12 cycles. The MIC was determined after each cycle.
In parallel, the same experimental protocol was used but ceftriaxone
was added at a low concentration (0.03 mg/L corresponding to 1/16 MIC
for the two strains) to the tubes containing serial dilutions of levoflox-
acin. After 12 h of incubation, the MIC of levofloxacin was determined as
described above in tubes containing only levofloxacin.
Preparation of chromosomal DNA, PCR amplification and 
DNA sequence analysis
Chromosomal pneumococcal DNA was prepared as described previ-
ously.15 PCR amplification of the parC, parE, gyrA and gyrB genes was
performed according to a published method.16 PCR amplification was
performed with a GeneAmp PCR system 9700 apparatus (Perkin-Elmer).
After amplification, PCR products were purified using a QIAquick PCR
purification kit (Qiagen AG, Basel, Switzerland). Nucleotide sequencing
for the PCR amplicons was carried out with the ABI PRISM Dye Termin-
ator Cycle Sequencing Ready Reaction kit according to the protocol of
the manufacturer (Perkin-Elmer). An ABI PRISM 377 DNA sequencer
was used for sequencing. All testing was performed in duplicate.
Results
One injection of ceftriaxone (125 mg/kg) led to peak CSF levels after
2 h: around 5.2 mg/L decreasing slowly to 3.0 mg/L at the end of the
treatment period. During the total treatment period, ceftriaxone CSF
levels remained far above the MIC. The peak and trough CSF/MIC
ratios were 10.4 and 6, respectively. After one injection of 10 mg/kg
levofloxacin, CSF levels peaked at 3.3 mg/L, decreasing slowly to
1.3 mg/L after 8 h.
The efficacy of the different regimens in rabbit meningitis are
summarized in Table 1. In untreated controls, a slight increase in bac-
terial titres was observed over 8 h (+0.29 ± 0.10 ∆log10 cfu/mL).
Ceftriaxone produced only moderate bactericidal activity (–0.30 ±
0.09 ∆log10 cfu/mL.h) without sterilizing the CSF of rabbits after
8 h (0 out of 9). Levofloxacin monotherapy produced significantly
(P = 0.0085) higher antibacterial activity than ceftriaxone monotherapy,
but managed to sterilize the CSF of only one rabbit. The combination
regimen (ceftriaxone combined with levofloxacin) produced highly
bactericidal activity, significantly superior compared with the mono-
therapies (P < 0.01 versus either monotherapy) and sterilized the CSF
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of eight out of nine rabbits at the end of the treatment period. In
time–killing assays in vitro, antibiotic concentrations were chosen
(ceftriaxone: 1/2× MIC and levofloxacin: 1× MIC) to produce only
marginal intrinsic bactericidal activity in order to demonstrate poten-
tial synergy between the two compounds. Synergy was defined as the
bactericidal effect of a drug combination significantly exceeding the
sum of the bactericidal effects of each monotherapy.13 Against WB4,
ceftriaxone (1/2× MIC) produced a slight decrease in the viable cell
count over 8 h (–0.8 log10 cfu/mL) (Figure 1). Levofloxacin mono-
therapy was more bactericidal with a decrease in bacterial titres
around –3.9 log10 cfu/mL. The combination was highly bactericidal
and acted synergistically (–6.9 log10 cfu/mL), sterilizing the cultures
after 8 h. Against KR4, the synergistic activity of the combination was
even more pronounced, sterilizing all cultures after 4 h (Figure 2).
Ceftriaxone monotherapy was also more active against KR4 than
against WB4 (–2.4 versus 0.8 log10 cfu/mL, respectively).
In addition, synergy between levofloxacin and ceftriaxone was
demonstrated for both strains using the chequerboard method, with
FIC indices of 0.25.
Based on a previous experimental setting,17 levofloxacin-resistant
mutants were selected in both WB4 and KR4 by sequential exposure
to different levofloxacin concentrations over 12 cycles. In WB4
(Figure 3a), the MIC of levofloxacin increased to 8 mg/L after four
cycles; after seven cycles, it increased to 64 mg/L and remained
stable until the end of the experiment. In contrast, the MIC increased
to a lesser extent with the addition of a low concentration of ceftri-
axone (1/16 MIC). This latter concentration of ceftriaxone was the
highest that allowed bacterial growth of pneumococcal cultures incu-
bated with different concentrations of levofloxacin. After 12 cycles,
the MIC was 16 mg/L. The increase in the MIC in the different
treatment groups was confirmed by gene mutations: sequential
exposure of WB4 to levofloxacin led to mutations in the target genes
encoding for topoisomerase IV and gyrase (Ser79→Phe in parC and
Glu85→Lys in gyrA). In the combination treatment, mutations in
parE (Asp435→Asn) and gyrA (Ser81→Phe) were detected (see
Table 2). In the second strain, KR4, the selection of levofloxacin-
resistant mutants was comparable. In the monotherapy group, the MIC
of levofloxacin increased to 8 mg/L after four cycles and to 64 mg/L
after nine cycles (Figure 3b). Analagous to WB4, the addition of ceftri-
axone (1/16 MIC) led to an MIC increase to 16 mg/L after 12 cycles.
In the monotherapy group, two mutations in parC (Ser79→Phe and
Asp83→Tyr) and one mutation in gyrA (Glu85→Lys) were detected.
In the combination regimen, mutations in parE (Asp435→Asn) and
gyrA (Ser81→Phe) were found. It is interesting to note that the addi-
tion of ceftriaxone at a low concentration (1/16 MIC) did not lower
the MIC of levofloxacin. On the other hand, no cross-resistance
Table 1. Single drug and combination therapy against penicillin-resistant Streptococcus pneumoniae WB4 in experimental 
meningitis
aP < 0.05 versus all groups.
bP < 0.05 levofloxacin + ceftriaxone versus all monotherapies.
Antibiotic n
Initial titre (log10 cfu/mL; 
means ± S.D.)
Killing rate (∆log10 cfu/mL·h; 
means ± S.D.)
Killing rate/8 h (log10 cfu/mL; 
means ± S.D.)
Controls 5 6.05 ± 0.50 +0.10 ± 0.50a +0.29 ± 0.10a
Ceftriaxone 9 5.85 ± 0.45 –0.30 ± 0.09b –2.20 ± 0.45b
Levofloxacin 9 6.11 ± 0.93 –0.45 ± 0.12b –3.45 ± 0.76b
Levofloxacin + ceftriaxone 9 5.63 ± 0.20 –0.64 ± 0.07b –5.33 ± 0.64b
Figure 1.
 Killing rates of ceftriaxone (CRO 1/2× MIC), levofloxacin (LVX 1×
MIC) and ceftriaxone combined with levofloxacin (CRO + LVX) for the penicil-
lin-resistant strain WB4. Experiments were performed in triplicate, and killing
rates are expressed as means ± S.D.
Figure 2.
 Killing rates of ceftriaxone (CRO 1/2× MIC), levofloxacin (LVX 1×
MIC) and ceftriaxone combined with levofloxacin (CRO + LVX) for the penicil-
lin-resistant strain KR4. Experiments were performed in triplicate, and killing
rates are expressed as means ± S.D.
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between levofloxacin and ceftriaxone has been detected. The MIC
of ceftriaxone was not affected by serial incubation of these two
pneumococcal strains with levofloxacin (Table 3).
Discussion
In recent decades, pneumococci have developed several strategies to
survive the pressure of numerous therapeutic modalities. They are
able to resist β-lactam antibiotics by modifying the structure of bac-
terial cell-wall-synthesizing enzymes [also called penicillin-binding
proteins (PBPs)] and the action of quinolones either by point muta-
tions in the genes (gyrA, gyrB, parC, parE) or by activating efflux
pumps to prevent intracellular accumulation of the drug. The emer-
gence of vancomycin- and cephalosporin-tolerant strains, leading to
treatment failure in cases of pneumococcal meningitis, has jeopard-
ized the efficacy of this antibiotic combination, usually recom-
mended as empirical treatment for meningitis. Furthermore, the
emergence of quinolone resistance during therapy might undermine
the use of quinolones as monotherapy for pneumococcal diseases.4
The aim of this study was to evaluate a highly bactericidal regimen,
which is a prerequisite for the treatment of pneumococcal meningitis,
avoiding the risk of development of resistance at the same time.
The doses of ceftriaxone and levofloxacin were standard, mimick-
ing levels achieved in humans. One injection of ceftriaxone led to
CSF levels in rabbits in the range 5.2–3 mg/L, corresponding to levels
measured in humans with bacterial meningitis.18 CSF levels obtained
with one injection of levofloxacin were slightly higher than those
measured in humans after 500 mg twice daily (peak levels: 3.3 mg/L
in rabbits versus 2.56–1.29 mg/L in humans).19
An interesting feature of this study was the efficacy of the com-
bination regimen compared with the monotherapy in experimental
meningitis (–5.33 ∆log10 cfu/mL.8 h for the combination regimen
versus –2.20 ∆log10 cfu/mL.8 h for ceftriaxone and –3.45 ∆log10
cfu/mL.8 h for levofloxacin), sterilizing the majority of the CSF of
rabbits (eight out of nine). Ceftriaxone monotherapy produced kill-
ing rates similar to those published in previous studies against the
same strain.12,20,21 Compared with a previous study, levofloxacin
monotherapy produced slightly higher killing rates, although the CSF
peak levels were in the same range.22
In vitro, synergy was equal between ceftriaxone and levofloxacin
in time–killing assays and with the chequerboard method with FIC
indices of 0.25 for both strains.
An interesting aspect of this study was the effect of ceftriaxone,
added at a low concentration (1/16 MIC), on the development of
levofloxacin-induced resistance in vitro. The choice of the low con-
centration of ceftriaxone was based on results observed in the
chequerboard experiments.
In cycling experiments with both strains, levofloxacin led to a step-
wise increase of resistance until high-level resistance (MIC 64 mg/L)
was reached at the end of the experimental period (12 cycles). The
increase in resistance correlated with the sequential emergence of
point mutations in genes encoding the two target enzymes, i.e. topo-
isomerase IV and gyrase. All mutations described in Table 2 have
been mentioned in the literature.
In both strains, ceftriaxone prevented the emergence of mutations
in parC but led to mutations in parE (Asp435→Asn). This mutation,
which has been described in other isolates, selected after cycling with
levofloxacin,23 seemed to contribute to a lesser extent to the MIC
increase. The effect of the β-lactam antibiotic, i.e. ceftriaxone added
at a low concentration, on levofloxacin-induced resistance is not
understood completely. Two explanations are conceivable: (i) the
synergy between the two antibiotics might cause the bacterial popu-
Table 2. Mutations in topoisomerase IV (parC and parE ) and 
gyrase (gyrA and gyrB) genes before and after cyclic exposure to 
levofloxacin (LVX) alone or in combination with ceftriaxone 
(CRO) in two penicillin-resistant pneumoccocal strains (WB4 
and KR4)
Strain parC parE gyrA gyrB
WB4 none none none none
WB4 LVX Ser79→Phe none Glu85→Lys none
WB4 LVX+ 
CRO
none Asp435→Asn Ser81→Phe none
KR4 none none none none




none Asp435→Asn Ser81→Phe none
Figure 3.
 The selection of levofloxacin-resistant mutants of Streptococcus
pneumoniae WB4 (a) and KR4 (b) exposed to stepwise increasing concentrations
of levofloxacin alone or in combination with a sub-MIC concentration (1/16× MIC)
of ceftriaxone.
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lations to decrease below a critical threshold for longer, i.e. below
106–107 cfu/mL where mutations occur; (ii) the combined antibac-
terial effect of antibiotics interfering with different targets (PBPs or
gyrase and topoisomerase IV) might impede the development of
mutations in the microorganism. The last hypothesis is probably the
more unlikely because the MIC of levofloxacin was not affected by
the addition of ceftriaxone (see Table 3).
The observation that antibiotics interfering with the cell wall syn-
thesis might influence quinolone-induced resistance in pneumococci
is not new. In the same experimental setting, we have shown pre-
viously that the addition of vancomycin reduced ciprofloxacin- and
trovafloxacin-induced resistance in the strain WB4.17
In summary, we have demonstrated that a combination of ceftri-
axone and levofloxacin was very efficacious in experimental pneu-
mococcal meningitis and reduced the risk of quinolone-induced
resistance. This combination might be used in the future as empirical
treatment in bacterial meningitis, as an alternative to the recom-
mended regimen based on ceftriaxone and vancomycin.
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